What question did this study set out to answer?

To evaluate the emerging therapeutic role and pharmacological efficacy of third-generation aromatase inhibitors compared to standard tamoxifen therapy in postmenopausal women with breast cancer.

June 11, 2003New England Journal of Medicine

Aromatase Inhibitors in Breast Cancer

View Full Paper

Ask AI

Bookmark

To evaluate the emerging therapeutic role and pharmacological efficacy of third-generation aromatase inhibitors compared to standard tamoxifen therapy in postmenopausal women with breast cancer.
Narrative synthesis of clinical and pharmacological evidence on endocrine treatments for breast cancer.
Evaluation of modern aromatase inhibitors, including letrozole, anastrozole, and exemestane, relative to earlier agents like aminoglutethimide and tamoxifen.
Newer aromatase inhibitors exhibit significantly higher potency and target specificity compared to first-generation agents such as aminoglutethimide.
Agents including letrozole, anastrozole, and exemestane are actively redefining standard endocrine management paradigms for postmenopausal breast cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Review demonstrates superior utility of aromatase inhibitors over tamoxifen in postmenopausal breast cancer, highlighting major advances in endocrine therapy.

Cite This Study

Smith et al. (2003) studied this question.

synapsesocial.com/papers/6a12fc23c031bb6829a7a7b1 https://doi.org/10.1056/nejmra023246

View Full Paper

Ask AI

Bookmark

Implication

Review demonstrates superior utility of aromatase inhibitors over tamoxifen in postmenopausal breast cancer, highlighting major advances in endocrine therapy.

Aromatase Inhibitors in Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Aromatase Inhibitors in Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider